A Phase 2a to Evaluate the Safety of MEDI8852 in Adults with Uncomplicated Influenza - MEDI8852

Inclusion Criteria

• -Age 18 through 65 years at the time of screening.
• -Symptomatic presumptive Influenza A infection with onset of symptoms less than or equal to (≤) 5 days prior to MEDI8852 administration and defined as the presence of:
• -Fever of greater than or equal to (≥) 38.0 degrees Celsius (100.4 degrees Fahrenheit) at screening AND
• - ≥ 1 moderate systemic symptom (headache, malaise, myalgia, sweats and/or chills, or fatigue) AND
• - ≥ 1 moderate respiratory symptom (cough, sore throat, or nasal symptoms)
• -Influenza A infection confirmed with positive rapid antigen test
• -Able to complete the follow-up period through Day 101 as required by protocol (including telephone follow-up for Days 11 to 101)
• -Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception for at least 2 days prior to the first dose of investigational product and must agree to continue using such precautions through Day 101 of the study